Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove Licenses Microarray from Stanford, Gets Patent

NEW YORK, July 15 (GenomeWeb News) - BioTrove announced Thursday that it has acquired an exclusive license from Stanford University for patent applications covering the use of a through-hole structured microarray to perform PCR.

 

BioTrove also said it has received a patent on a novel method using the company's proprietary OpenArray platform for high-density cell assay and culture. BioTrove is commercializing the platform, a nanofluidic system for massively parallel analysis using Thru-Hole technology, for use by life science researchers.

 

The patent covers an innovative application of the OpenArray technology that allows for the maintenance and growth of cells in a microfluidic environment, with potential application in cell-based assays.

 

BioTrove's through-hole intellectual property portfolio now includes eight patents issued or allowed and numerous patents pending, according to the Woburn, Mass.-based firm.

 

 

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.